Skip to main content
. 2021 May 16;55(5):926–935. doi: 10.1007/s43441-021-00277-w

Figure 1.

Figure 1

Schematic of Beat AML flow of information, and of patients into the Sub-Studies, and the flow of pharmacokinetic samples. Following screening (cytogenetics and next-generation sequencing) and central treatment decision, patients were enrolled into the 13 sub-studies where they were treated with one of the 9 investigational targeted therapies as monotherapy and/or combination therapy with either azacitidine or decitabine